Life Sciences Experience
- Conducting IP due diligence reviews of small-molecule companies for potential acquisition by large pharmaceutical companies.
- Representing start-up and midsize pharmaceutical companies through IP due diligence reviews for $14M, $16M and $40M venture capital financings.
- Actively participating in global patent strategy meetings related to commercial products of several large pharmaceutical companies.
- Representing a monoclonal antibody company in IP matters in its $400M acquisition by a major pharmaceutical company.
- Representing an antibiotics company in IP matters in the establishment of a $127M collaboration with a major pharmaceutical company.
- Representing an emerging biotech company in IP matters in connection with a $40M financing.
- Representing a biotech drug discovery company in IP matters in connection with its $55M acquisition by a pharmaceutical company.
- Participating in the due diligence, documentation, and integration phases of multimillion-dollar acquisitions of start-up companies by multinational pharmaceutical companies.
- Preparing a sponsorship and intellectual property agreement between a research and development biotechnology company focused on tissue engineering and a major university.
- Conducting an IP due diligence review of an antibody-based biotech start-up for a syndicate of venture capital firms involved in a multimillion-dollar financing.
- Representing a venture capital firm in its multimillion-dollar financing of a Switzerland-based antibody discovery company.
- Representing a privately held antibody library/affinity maturation company in its multimillion-dollar acquisition by one of the world's leading research-based pharmaceutical companies.
- Representing a venture capital syndicate in its multimillion-dollar financing of a Cambridge, MA-based antibody therapeutic company.
- Representing a Japanese pharmaceutical company in an IP due diligence review of an antibody discovery company in preparation for its multimillion-dollar acquisition.
- Conducting IP due diligence reviews of pharmaceutical companies for potential partnering on second- and third-generation drug formulations.
- Representing start-up pharmaceutical companies throughout their drug development activities and throughout IP due diligence with large pharmaceutical companies leading to several multimillion-dollar acquisitions and distribution rights deals.
- One of our clients, the University of Massachusetts Medical School, holds several patents and patent applications in the field of RNA interference (RNAi), including Dr. Craig Mello's seminal patents relating to the discovery of RNAi, for which he and Dr. Andrew Fire recently received the Nobel Prize in Medicine. We represent the university's interests in this exciting technological field.
- Representing a leading Boston, MA-based venture capital firm in IP due diligence for its $40M investment in a European biotech company.
- Representing a Canadian biotechnology company in IP matters in connection with a private placement financing and its IPO.
- Representing a start-up biotech company in a significant venture financing by a leading New Jersey-based venture capital firm.
- Writing a patent application that covers a leading European biotechnology company’s antibody, which constituted the intellectual property for a $2 billion deal with a large pharmaceutical company.
- Developing an extensive international patent portfolio that covers a first-of-its kind human monoclonal antibody drug marketed by a large pharmaceutical company.
- Developing a patent portfolio for the leading producer of canned and bottled juice drinks in North America directed to nutraceutical products isolated from fruit seeds which have beneficial effects when administered to subjects, including treating and reducing the occurrence of breast cancer.
- Conducting key depositions on behalf of a leading global drug manufacturer in a Paragraph IV ANDA litigation involving mirtazapine.
- Serving as lead counsel for a multi-national drug manufacturer in obtaining a favorable settlement in a Paragraph IV ANDA litigation involving megestrol acetate.
- Representing a leading global drug manufacturer in achieving a favorable ruling on a dispositive motion in a Paragraph IV ANDA litigation involving hydrocodone and ibuprofen.
- Managing extensive pre-trial discovery and depositions on behalf of a leading global drug manufacturer in a Paragraph IV ANDA litigation involving ondansetron.
- Providing strategic advice to a Swiss biotech company throughout the sale of its ophthalmology unit and guiding the company through IP due diligence activities in a deal worth up to $500M.
- Representing a biopharmaceutical company in its exclusive worldwide licensing agreement with a global pharmaceutical company for the development and co-commercialization of a first-in-class, fully human monoclonal antibody in a deal worth up to $530M.
- Working with a clean technology company developing cellulos ethanol to develop and expand their patent portfolio.
- Conducting the IP due diligence for a leading gene therapy company in its $35 million Series B funding with new investors.
- Prosecuting a family of patent applications directed toward medical devices with biocompatible coatings that temper the immune response when the devices are implanted in the body.
- Developing a patent strategy and portfolio for a client that specializes in environmentally friendly techniques for converting biomass into components that can be used for fuel and industrial production.
